Michael Andriole
Chief Executive Officer at CHIMERIX, INC.
Net worth: 514 074 $ as of 2024-02-28
Profile
Michael T.
Andriole is President, Chief Executive Officer & Director at Chimerix, Inc.
Mr. Andriole previously was Vice President-Corporate Business Development at Eli Lilly & Co. and Chief Financial Officer for Endocyte, Inc.
He received an undergraduate degree from Williams College of Business and an MBA from Kelley School of Business.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
CHIMERIX, INC.
0.50% | 2024-02-13 | 447,021 ( 0.50% ) | 514 074 $ | 2024-02-28 |
Michael Andriole active positions
Companies | Position | Start |
---|---|---|
CHIMERIX, INC. | Chief Executive Officer | 2023-07-31 |
Former positions of Michael Andriole
Companies | Position | End |
---|---|---|
ENDOCYTE, INC. | Director of Finance/CFO | 2018-11-30 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 2017-01-31 |
Training of Michael Andriole
Kelley School of Business | Masters Business Admin |
Williams College of Business | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
CHIMERIX, INC. | Health Technology |
Private companies | 1 |
---|---|
Endocyte, Inc.
Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |